Urologix, Inc. (OTCPK:ULGX) will continue reviewing various strategic alternatives available to the Company, including the sale of the Company or its assets, partnering or other collaboration agreements, or a merger, reverse merger or other strategic transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -.--% |
2016 | A unknown buyer acquired substantially all of the operating assets of Urologix, Inc. | CI |
2015 | Urologix Conducting A Strategic Review | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 2.13K | |
+7.01% | 217B | |
+9.85% | 188B | |
+27.51% | 153B | |
+31.79% | 112B | |
-0.91% | 62.84B | |
+13.93% | 52.35B | |
+1.85% | 49.33B | |
+0.30% | 35.4B | |
+22.28% | 30.9B |
- Stock Market
- Equities
- ULGX Stock
- News Urologix, Inc.
- Urologix Conducting A Strategic Review